
Viking Therapeutics, Inc
VKTX
VKTX: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
moreShow VKTX Financials
Recent trades of VKTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by VKTX's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on VKTX's company Twitter account
Number of mentions of VKTX in WallStreetBets Daily Discussion
Recent insights relating to VKTX
Recent picks made for VKTX stock on CNBC
ETFs with the largest estimated holdings in VKTX
Flights by private jets registered to VKTX